MA40538A - Inhibiteurs de l'époxyde hydrolase soluble et utilisations de ceux-ci - Google Patents
Inhibiteurs de l'époxyde hydrolase soluble et utilisations de ceux-ciInfo
- Publication number
- MA40538A MA40538A MA040538A MA40538A MA40538A MA 40538 A MA40538 A MA 40538A MA 040538 A MA040538 A MA 040538A MA 40538 A MA40538 A MA 40538A MA 40538 A MA40538 A MA 40538A
- Authority
- MA
- Morocco
- Prior art keywords
- epoxide hydrolase
- soluble epoxide
- hydrolase inhibitors
- inhibitors
- soluble
- Prior art date
Links
- 229940127514 Epoxide Hydrolase Inhibitors Drugs 0.000 title 1
- 108020002908 Epoxide hydrolase Proteins 0.000 title 1
- 102100025357 Lipid-phosphate phosphatase Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462043275P | 2014-08-28 | 2014-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40538A true MA40538A (fr) | 2021-04-07 |
Family
ID=55400481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA040538A MA40538A (fr) | 2014-08-28 | 2015-08-26 | Inhibiteurs de l'époxyde hydrolase soluble et utilisations de ceux-ci |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10081616B2 (enExample) |
| EP (1) | EP3186228A4 (enExample) |
| JP (1) | JP2017525777A (enExample) |
| CN (2) | CN107074771B (enExample) |
| AU (2) | AU2015306643B2 (enExample) |
| CA (1) | CA2958881A1 (enExample) |
| MA (1) | MA40538A (enExample) |
| WO (1) | WO2016033150A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017525777A (ja) * | 2014-08-28 | 2017-09-07 | エックス−ケム，インコーポレーテッド | 可溶性エポキシドヒドロラーゼ阻害剤及びこれらの使用 |
| EP3600266B1 (en) * | 2017-03-30 | 2022-07-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions for use in the treatment of cardiovascular calcification |
| US20230071934A1 (en) * | 2019-12-18 | 2023-03-09 | Intra-Cellular Therapies, Inc. | Novel uses |
| WO2024105225A1 (en) | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3245950A1 (de) * | 1981-12-24 | 1983-07-07 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Verfahren zur herstellung substituierter pyridine |
| AR037233A1 (es) * | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
| US20040067985A1 (en) * | 2002-10-04 | 2004-04-08 | Fortuna Haviv | Method of inhibiting angiogenesis |
| JP2009528992A (ja) * | 2006-02-16 | 2009-08-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性エポキシド加水分解酵素阻害剤として有益な置換ピリジンアミン化合物 |
| CA2643859A1 (en) | 2006-03-10 | 2007-09-20 | Boehringer Ingelheim International Gmbh | Soluble epoxide hydrolase inhibitors and methods of using same |
| CN102516115B (zh) * | 2006-08-09 | 2016-05-11 | 史密丝克莱恩比彻姆公司 | 作为阿片样物质受体的拮抗剂或反向激动剂的新型化合物 |
| CA2672373C (en) * | 2006-12-19 | 2011-08-30 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| EP2002834A1 (de) * | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors |
| WO2009151800A1 (en) * | 2008-05-07 | 2009-12-17 | Merck & Co., Inc. | Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment |
| US20110306597A1 (en) * | 2008-06-18 | 2011-12-15 | James Michael Crawforth | Nicotinamide Derivatives |
| TW201010997A (en) * | 2008-06-18 | 2010-03-16 | Pfizer Ltd | Nicotinamide derivatives |
| EP2149552A1 (de) * | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
| EP2149551A1 (de) * | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
| US20100113512A1 (en) * | 2008-10-30 | 2010-05-06 | Diane Michele Ignar | Method of treatment using novel antagonists or inverse agonists at opioid receptors |
| WO2010080183A1 (en) | 2009-01-08 | 2010-07-15 | The Trustees Of Columbia University In The City Of New York | Potent non-urea inhibitors of soluble epoxide hydrolase |
| WO2011091410A1 (en) * | 2010-01-25 | 2011-07-28 | Glaxos Smithkline Llc | Trpv4 antagonists |
| US20130102600A1 (en) * | 2011-10-21 | 2013-04-25 | F. Hoffmann-La Roche Ltd | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| US20130102601A1 (en) * | 2011-10-21 | 2013-04-25 | F. Hoffmann-La Roche Ltd | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| US8809552B2 (en) * | 2011-11-01 | 2014-08-19 | Hoffmann-La Roche Inc. | Azetidine compounds, compositions and methods of use |
| WO2013112751A1 (en) * | 2012-01-25 | 2013-08-01 | The Trustees Of Columbia University In The City Of New York | Potent non-urea inhibitors of soluble epoxide hydrolase |
| KR20150085045A (ko) * | 2012-11-16 | 2015-07-22 | 메르크 파텐트 게엠베하 | 3-아미노시클로펜탄 카르복사미드 유도체 |
| CN104016914B (zh) * | 2014-05-27 | 2016-03-30 | 苏州科技学院 | 一种酰胺化合物的制备方法 |
| JP2017525777A (ja) * | 2014-08-28 | 2017-09-07 | エックス−ケム，インコーポレーテッド | 可溶性エポキシドヒドロラーゼ阻害剤及びこれらの使用 |
-
2015
- 2015-08-26 JP JP2017530962A patent/JP2017525777A/ja active Pending
- 2015-08-26 EP EP15837061.9A patent/EP3186228A4/en not_active Withdrawn
- 2015-08-26 AU AU2015306643A patent/AU2015306643B2/en not_active Ceased
- 2015-08-26 CN CN201580046202.2A patent/CN107074771B/zh not_active Expired - Fee Related
- 2015-08-26 MA MA040538A patent/MA40538A/fr unknown
- 2015-08-26 US US15/504,223 patent/US10081616B2/en not_active Expired - Fee Related
- 2015-08-26 CA CA2958881A patent/CA2958881A1/en not_active Abandoned
- 2015-08-26 CN CN202010138750.0A patent/CN111454246A/zh active Pending
- 2015-08-26 WO PCT/US2015/046878 patent/WO2016033150A1/en not_active Ceased
-
2018
- 2018-08-23 US US16/110,698 patent/US20180362499A1/en not_active Abandoned
-
2020
- 2020-07-22 AU AU2020207828A patent/AU2020207828A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015306643A1 (en) | 2017-03-16 |
| CN111454246A (zh) | 2020-07-28 |
| JP2017525777A (ja) | 2017-09-07 |
| EP3186228A1 (en) | 2017-07-05 |
| AU2020207828A1 (en) | 2020-08-13 |
| CN107074771A (zh) | 2017-08-18 |
| US20180362499A1 (en) | 2018-12-20 |
| US10081616B2 (en) | 2018-09-25 |
| EP3186228A4 (en) | 2018-04-18 |
| AU2015306643B2 (en) | 2020-05-07 |
| WO2016033150A1 (en) | 2016-03-03 |
| CN107074771B (zh) | 2020-03-20 |
| US20170240526A1 (en) | 2017-08-24 |
| CA2958881A1 (en) | 2016-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3129023T3 (da) | Potente opløselige epoxidhydrolase-inhibitorer | |
| IL256369A (en) | Novel crispr enzymes and systems | |
| EP3471727A4 (en) | CXCR4 INHIBITORS AND USES THEREOF | |
| EP3600273A4 (en) | CD73 INHIBITORS AND USES THEREOF | |
| EP3472129A4 (en) | CXCR4 INHIBITORS AND USES THEREOF | |
| MA44262A (fr) | Bioconjugués et utilisations de ceux-ci | |
| EP3389658A4 (en) | GLYCOSIDASE INHIBITORS AND USES THEREOF | |
| IL280863A (en) | Autotaxin inhibitors and uses thereof | |
| EP3317273A4 (en) | EGFR HEMMER AND METHOD OF USE THEREOF | |
| EP3334706A4 (en) | PILLARARES AND USES THEREOF | |
| EP3332008A4 (en) | CHANGE OF THE DYSTROPHINE GENE AND USES THEREOF | |
| EP3344624A4 (en) | Tyk2 inhibitors and uses thereof | |
| MA46700A (fr) | Variants polypeptidiques et ses utilisations | |
| PL3319813T3 (pl) | Dokumenty zabezpieczone i urządzenia zabezpieczające oraz sposób ich wytwarzania | |
| EP3356416A4 (en) | PD-1 ANTIBODIES AND USES THEREOF | |
| EP3445365A4 (en) | EZH2 INHIBITORS AND USES THEREOF | |
| MA40595A (fr) | Récepteurs chimériques et utilisations de ceux-ci en thérapie immunitaire | |
| EP3341387A4 (en) | SIALYL TRANSFERASE INHIBITORS AND USES THEREOF | |
| EP3471726A4 (en) | CXCR4 INHIBITORS AND USES THEREOF | |
| PT3319612T (pt) | Oxisteróis e métodos de utilização dos mesmos | |
| EP3426244A4 (en) | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | |
| DK3194564T3 (da) | Trichodermasammensætninger og anvendelsesfremgangsmåder | |
| EP3411391A4 (en) | UBIQUITIN VARIANTS AND USES THEREOF AS 53BP1 INHIBITORS | |
| EP3426243A4 (en) | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | |
| MA41022A (fr) | Ciblage lysosomial et utilisations correspondantes |